

## Study finds similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk

March 21 2023



Researchers find similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk. Credit: Reproductive Health Supplies Coalition (CC0, creativecommons.org/publicdomain/zero/1.0/)



There is a relative increase of 20% to 30% in breast cancer risk associated with both combined and progestogen-only contraceptives, whatever the mode of delivery, though with five years of use, the 15-year absolute excess incidence is at most 265 cases per 100,000 users. The results appear in a new study published March 21 in the open access journal *PLOS Medicine* by Kirstin Pirie of University of Oxford, U.K., and colleagues.

Use of combined oral contraceptives, containing both estrogen and progestogen, has previously been associated with a small increase in breast cancer risk but there is limited data about the effect of progestogen-only hormonal contraceptives. However, the use of progestogen-only contraceptives has increased substantially in recent years, with almost as many prescriptions in England for oral progestogen-only contraceptives as for combined oral contraceptives in 2020.

In the new study, researchers analyzed data from a U.K. primary care database, the Clinical Practice Research Datalink (CPRD), on 9,498 women under the age of 50 with <u>invasive breast cancer</u> diagnosed in 1996–2017, as well as data on 18,171 closely matched controls.

On average, 44% of women with breast cancer and 39% of matched controls had a hormonal contraceptive prescription, with about half the prescriptions being for progestogen-only preparations. With five years use of either oral combined or progestogen-only contraceptives, the associated 15-year absolute excess incidence of breast cancer was estimated at 8 cases per 100,000 hormonal contraceptive users at age 16–20 years and 265 cases per 100,000 users at age 35–39 years.

The odds of breast cancer were similarly and significantly raised, regardless of whether the contraceptive used was a combined (estrogen and progestogen) oral preparation (OR=1.23 95%CI 1.14–1.32, p



Citation: Study finds similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk (2023, March 21) retrieved 25 April 2024 from <a href="https://medicalxpress.com/news/2023-03-similar-association-progestogen-only-combined-hormonal.html">https://medicalxpress.com/news/2023-03-similar-association-progestogen-only-combined-hormonal.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.